Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Data Integrity & Digital Quality XGene CMC Intelligence Data Integrity & Digital Quality ALCOA+, audit trails, electronic records and data governance. Featured analysis ALCOA+ — What FDA Finds When It Opens Your Data Integrity Files Data Integrity Warning Letter Remediation: Rebuilding Credibility After a GMP Finding Huons Co. Warning Letter: Data Integrity and the CMC Pattern Every Sterile Products Quality Director Must Recognize Wizcure Pharmaa Warning Letter ALCOA+ Attributability — Why Shared Logins Become Warning Letters ALCOA+ Data Completeness — The Deletion Problem FDA Finds First Annex 11 vs 21 CFR Part 11 Audit Trail Architecture — What a Defensible System Looks Like Current regulatory intelligence Wizcure Pharmaa Warning Letter: Data Integrity and the CMC Pattern Every Sterile OTC Drug Quality Director Must Recognize Request a Data Integrity Assessment
Huons Co. Warning Letter: Data Integrity and the CMC Pattern Every Sterile Products Quality Director Must Recognize
Wizcure Pharmaa Warning Letter: Data Integrity and the CMC Pattern Every Sterile OTC Drug Quality Director Must Recognize
